A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Completed
Novartis Pharmaceuticals
Phase 2
2012-04-05
This study assessed the safety and efficacy of escalating doses INC280 when added to
gefitinib in patients with lung cancer that were known to have dysregulation of the c-MET
pathway and who had failed after benefiting on a prior treatment with either gefitinib or
erlotinib.
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Terminated
Adil Daud
Phase 2
2015-03-26
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work
in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib,
regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Terminated
University of California, San Francisco
Phase 2
2015-03-26
This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work
in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib,
regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Completed
Novartis
Phase 2
2016-05-01
This research study is studying capmatinib as a treatment for advanced non-small cell lung
cancer with MET exon 14 skipping, where the participant has already received prior therapy
with a MET inhibitor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
